Acute pancreatitis due to diabetes: The role of hyperglycaemia and insulin resistance

Pancreatology

Volumn 12, Issue 3, 2012, Pages 234-239

  Solanki, Nicholas S ^a   Barreto, Savio G ^b   Saccone, Gino T P ^c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b MODBURY HOSPITAL   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Acidosis; Hypertriglyceridaemia; Obesity; Oral hypoglycaemics; Stellate cells

Indexed keywords

AMYLIN; CALCITONIN GENE RELATED PEPTIDE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCRETIN; INTERLEUKIN 6; LEPTIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ACINAR CELL; ACUTE PANCREATITIS; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE PREDISPOSITION; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; META ANALYSIS; METABOLIC SYNDROME X; MORBIDITY; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 84862166082     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2012.01.003     Document Type: Conference Paper

References (92)

1. Barreto SG, Rodrigues J. Acute pancreatitis in Goaea hospital-based study. J Indian Med Assoc 2008;106:575-6 [578].
2. Barreto SG, Rodrigues J. Comparison of apache ii and imrie scoring systems in predicting the severity of acute pancreatitis. World J Emerg Surg 2007;2:33.
3. Barreto SG, Carati CJ, Schloithe AC, Toouli J, Saccone GT. The combination of neurokinin-1 and galanin receptor antagonists ameliorates caerulein-induced acute pancreatitis in mice. Peptides 2010;31:315-21.
4. Barreto SG, Carati CJ, Schloithe AC, Toouli J, Saccone GT. Octreotide negates the benefit of galantide when used in the treatment of caerulein-induced acute pancreatitis in mice. HPB (Oxford) 2010;12:403-11.
5. Barreto S, Carati C, Schloithe A, Mathison R, Davison J, Toouli J, et al. The efficacy of combining feg and galantide in mild caerulein-induced acute pancreatitis in mice. Peptides; 2010.
6. Shumacker HB. Acute pancreatitis and diabetes. Ann Surg 1940;112:177-200.
7. Renner IG, Savage 3rd WT, Pantoja JL, Renner VJ. Death due to acute pancreatitis. A retrospective analysis of 405 autopsy cases. Dig Dis Sci 1985; 30:1005-18. (Pubitemid 16225044)
8. Gorelick FS. Diabetes mellitus and the exocrine pancreas. Yale J Biol Med 1983;56:271-5. (Pubitemid 14160309)
9. Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010;12:766-71.
10. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin. Diabetes Care 2010;33:2349-54.
11. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011;106:1697-704.
12. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-8.
13. Martínez J, Johnson C, Sánchez-Payá J, de Madaria E, Robles-Díaz G, Pérez- Mateo M. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. Pancreatology 2006;6:206-9. (Pubitemid 44114487)
14. Huang DB, Raskin P. Diabetic hypertriglyceridemia-induced acute pancreatitis masquerading as biliary pancreatitis. J Diabetes Complications 2002;16: 180-2. (Pubitemid 34224123)
15. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-61.
16. Barreto SG, Tiong L, Williams R. Drug-induced acute pancreatitis in a cohort of 328 patients. A single-centre experience from Australia. JOP 2011;12:581-5.
17. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91. (Pubitemid 24340510)
18. Lin Y, Sun Z. Current views on type 2 diabetes. J Endocrinol 2009;204:1-11.
19. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68.
20. Barreto SG, Carati CJ, Toouli J, Saccone GT. The islet-acinar axis of the pancreas: more than just insulin. Am J Physiol Gastrointest Liver Physiol 2010; 299:G10-22.
21. Han J, Liu YQ. Suppressed glucose metabolism in acinar cells might contribute to the development of exocrine pancreatic insufficiency in streptozotocininduced diabetic mice. Metabolism 2010;59:1257-67.
22. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
23. Haddad NG, Croffie JM, Eugster EA. Pancreatic enzyme elevations in children with diabetic ketoacidosis. J Pediatr 2004;145:122-4. (Pubitemid 38962464)
24. Kamboj SS, Sandhir R. Protective effect of n-acetylcysteine supplementation on mitochondrial oxidative stress and mitochondrial enzymes in cerebral cortex of streptozotocin-treated diabetic rats. Mitochondrion 2011;11:214-22.
25. Yu T, Jhun BS, Yoon Y. High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid Redox Signal 2011;14:425-37.
26. Sugimoto R, Enjoji M, Kohjima M, Tsuruta S, Fukushima M, Iwao M, et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int 2005;25:1018-26. (Pubitemid 41404025)
27. Nomiyama Y, Tashiro M, Yamaguchi T, Watanabe S, Taguchi M, Asaumi H, et al. High glucose activates rat pancreatic stellate cells through protein kinase c and p38 mitogen-activated protein kinase pathway. Pancreas 2007;34: 364-72. (Pubitemid 46588263)
28. Halangk W, Lerch MM. Early events in acute pancreatitis. Gastroenterol Clin North Am 2004;33:717-31. (Pubitemid 39446595)
29. Saluja AK, Saluja M, Printz H, Zavertnik A, Sengupta A, Steer ML. Experimental pancreatitis is mediated by low-affinity cholecystokinin receptors that inhibit digestive enzyme secretion. Proc Natl Acad Sci U S A 1989;86:8968-71. (Pubitemid 20010347)
30. Morisset J, Wong H, Walsh JH, Laine J, Bourassa J. Pancreatic cck(b) receptors: their potential roles in somatostatin release and delta-cell proliferation. Am J Physiol Gastrointest Liver Physiol 2000;279:G148-56. (Pubitemid 30612693)
31. Barreto SG, Carati CJ, Schloithe AC, Toouli J, Saccone GT. Galanin potentiates supramaximal caerulein-stimulated pancreatic amylase secretion via its action on somatostatin secretion. Am J Physiol Gastrointest Liver Physiol 2009;297:G1268-73.
32. Kollind M, Adamson U, Lins PE. Somatostatin reduces posthypoglycemic insulin resistance in insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1988;118:173-8.
33. Kollind M, Moberg E, Lins PE, Adamson U. Exogenous somatostatin raises plasma insulin levels in patients with insulin-dependent diabetes mellitus. Horm Metab Res 1990;22:581-3.
34. Rakonczay Jr Z, Hegyi P, Takacs T, McCarroll J, Saluja AK. The role of NFkappaB activation in the pathogenesis of acute pancreatitis. Gut 2008;57: 259-67. (Pubitemid 351158056)
35. Karin M, Delhase M. The i kappa B kinase (ikk) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000;12:85-98. (Pubitemid 30114019)
36. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of ikkbeta. Science 2001;293:1673-7. (Pubitemid 32807849)
37. Grewal HP, Kotb M, el Din AM, Ohman M, Salem A, Gaber L, et al. Induction of tumor necrosis factor in severe acute pancreatitis and its subsequent reduction after hepatic passage. Surgery 1994;115:213-21. (Pubitemid 24057491)
38. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia- Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link tnfalpha. Arch Physiol Biochem 2008;114:183-94. (Pubitemid 352009305)
39. Phillips AR, Abu-Zidan FM, Bonham MJ, Cooper GJ, Windsor JA. Amylin and severe acute pancreatitis. Pancreas 2000;20:105-6. (Pubitemid 30022651)
40. Funakoshi A, Miyasaka K, Kitani K, Nakamura J, Funakoshi S, Fukuda H, et al. Stimulatory effects of islet amyloid polypeptide (amylin) on exocrine pancreas and gastrin release in conscious rats. Regul Pept 1992;38:135-43.
41. Svensson AM, Sandler S, Jansson L. Pancreatic islet blood flow in the rat after administration of islet amyloid polypeptide or calcitonin gene-related peptide. Diabetes 1994;43:454-8. (Pubitemid 24064255)
42. Cai K, Qi D, Wang O, Chen J, Liu X, Deng B, et al. TNF-alpha acutely upregulates amylin expression in murine pancreatic beta cells. Diabetologia 2011;54: 617-26.
43. Wick EC, Hoge SG, Grahn SW, Kim E, Divino LA, Grady EF, et al. Transient receptor potential vanilloid 1, calcitonin gene-related peptide, and substance p mediate nociception in acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2006;290:G959-69.
44. Warzecha Z, Dembinski A, Ceranowicz P, Konturek PC, Stachura J, Tomaszewska R, et al. Calcitonin gene-related peptide can attenuate or augment pancreatic damage in caerulein-induced pancreatitis in rats. J Physiol Pharmacol 1999;50:49-62. (Pubitemid 29162054)
45. German JP, Wisse BE, Thaler JP, Oh IS, Sarruf DA, Ogimoto K, et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes 2010;59:1626-34.
46. Tukiainen E, Kylanpaa ML, Ebeling P, Kemppainen E, Puolakkainen P, Repo H. Leptin and adiponectin levels in acute pancreatitis. Pancreas 2006;32:211-4.
47. Duarte-Rojo A, Lezama-Barreda A, Ramirez-Iglesias MT, Pelaez-Luna M, Robles-Diaz G. Is leptin related to systemic inflammatory response in acute pancreatitis? World J Gastroenterol 2006;12:4392-6. (Pubitemid 44194535)
48. Bhatia M. Novel therapeutic targets for acute pancreatitis and associated multiple organ dysfunction syndrome. Curr Drug Targets Inflamm Allergy 2002;1:343-51.
49. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000;190:117-25. (Pubitemid 30082483)
50. Bhatia M, Brady M, Kang YK, Costello E, Newton DJ, Christmas SE, et al. MCP-1 but not CINC synthesis is increased in rat pancreatic acini in response to cerulein hyperstimulation. Am J Physiol Gastrointest Liver Physiol 2002;282: G77-85. (Pubitemid 34650101)
51. Bhatia M, Wong FL, Cao Y, Lau HY, Huang J, Puneet P, et al. Pathophysiology of acute pancreatitis. Pancreatology 2005;5:132-44. (Pubitemid 40754730)
52. Shimada M, Andoh A, Hata K, Tasaki K, Araki Y, Fujiyama Y, et al. Il-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol 2002;168:861-8. (Pubitemid 34049589)
53. Uhl W, Warshaw A, Imrie C, Bassi C, McKay CJ, Lankisch PG, et al. IAP guidelines for the surgical management of acute pancreatitis. Pancreatology 2002;2:565-73. (Pubitemid 35365347)
54. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-92. (Pubitemid 27469668)
55. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002;45:805-12.
56. Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, et al. Interleukin-8 and development of adult respiratory distress syndrome in atrisk patient groups. Lancet 1993;341:643-7. (Pubitemid 23083243)
57. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000;47: 546-52.
58. Jambrik Z, Gyongyosi M, Hegyi P, Czako L, Takacs T, Farkas A, et al. Plasma levels of il-6 correlate with hemodynamic abnormalities in acute pancreatitis in rabbits. Intensive Care Med 2002;28:1810-8. (Pubitemid 35435486)
59. Pezzilli R, Miniero R, Cappelletti O, Barakat B. Serum interleukin 6 in the prognosis of acute biliary pancreatitis. Ital J Gastroenterol Hepatol 1998;30: 291-4. (Pubitemid 28395742)
60. Suzuki S, Miyasaka K, Jimi A, Funakoshi A. Induction of acute pancreatitis by cerulein in human IL-6 gene transgenic mice. Pancreas 2000;21:86-92. (Pubitemid 30421939)
61. Shenoy SD, Cody D, Rickett AB, Swift PGF. Acute pancreatitis and its association with diabetes mellitus in children. J Pediatr Endocrinol Metab 2004;17: 1667-70. (Pubitemid 40044906)
62. Nair S, Pitchumoni CS. Diabetic ketoacidosis, hyperlipidemia, and acute pancreatitis: the enigmatic triangle. Am J Gastroenterol 1997;92:1393-4.
63. Gianfrate L. Ferraris: acute pancreatitis, hyperlipidemia, and diabetic ketoacidosis: who comes first? Am J Gastroenterol 1998;92:1393-4. (Pubitemid 29076961)
64. Bhoomagoud M, Jung1 T, Atladottir J, Kolodecik TR, Shugrue C, Chaudhuri A, et al. Reducing extracellular pH sensitizes the acinar cell to secretagogueinduced pancreatitis responses in rats. Gastroenterology 2009;137:1083-92.
65. Lois K, Kumar S. Obesity and diabetes. Endocrinol Nutr 2009;56(Suppl. 4): 38-42.
66. Tomkin GH, Owens D. Insulin and lipoprotein metabolism with special reference to the diabetic state. Diabetes Metab Rev 1994;10:225-52. (Pubitemid 24306135)
67. Bierman EL, Porte Jr D, Bagdade JD. Hypertriglyceridemia and glucose intolerance in man. Horm Metab Res 1970;2(Suppl. 2):209-12.
68. Porte Jr D, Kahn SE. Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatmentean update. Am J Med 1991;90:8S-14S.
69. Franco-Pons N, Gea-Sorlí S, Closa D. Release of inflammatory mediators by adipose tissue during acute pancreatitis. J Pathol 2010;221:175-82.
70. Frossard J, Lescuyer P, Pastor CM. Experimental evidence of obesity as a risk factor for severe acute pancreatitis. World J Gastroenterol 2009;15:5260-5.
71. Sempere L, Martinez J, de Madaria E, Lozano B, Sanchez-Paya J, Jover R, et al. Obesity and fat distribution imply a greater systemic inflammatory response and a worse prognosis in acute pancreatitis. Pancreatology 2008; 8:257-64. (Pubitemid 351832478)
72. Ben M, Thabet H, Zaghodoudi I, Amamou M. Metformin associated acute pancreatitis. Vet Hum Toxicol 2002;44:47-8. (Pubitemid 34087787)
73. Mallick S. Metformin induced acute pancreatitis precipitated by renal failure. Postgrad Med J 2004;80:239-40. (Pubitemid 38561407)
74. Fimognari FL, Corsonello A, Pastorell R, Antonelli-Incalzi R. Metformininduced pancreatitis: a possible adverse drug effect during acute renal failure. Diabetes Care 2006;29:1183.
75. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf 2008;31:823-37.
76. Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care 2010;16: S187-94.
77. Anderson S, Trujillo J. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010;44:904-9.
78. Ayoub W, Kumar A, Naguib H, Taylor H. Exenatide-induced acute pancreatitis. Endocr Pract 2010;16:80-3.
79. Tatarkiewicz K, Smith P, Sablan E, Polizzi C, Aumann D, Villescaz C, et al. Exenatide does not evoke pancreatitis and attenuates chemically-induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010;299:E1076-86.
80. Koehler J, Baggio L, Lamont B, Ali S, Drucker D. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009;58:2148-61.
81. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutideethe FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7.
82. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011;45:e22.
83. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25: 1019-27.
84. Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-90.
85. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol 2009;104: 984-91.
86. Hahn SJ, Park JH, Lee JH, Lee JK, Kim KA. Severe hypertriglyceridemia in diabetic ketoacidosis accompanied by acute pancreatitis: case report. J Korean Med Sci 2010;25:1375-8.
87. Monga A, Arora A, Makkar RP, Gupta AK. Hypertriglyceridemia-induced acute pancreatitisetreatment with heparin and insulin. Indian J Gastroenterol 2003; 22:102-3. (Pubitemid 36775720)
88. Jain D, Zimmerschied J. Heparin and insulin for hypertriglyceridemia- induced pancreatitis: case report. ScientificWorldJournal 2009;9:1230-2.
89. Stone BG, Gavaler JS, Belle SH, Shreiner DP, Peleman RR, Sarva RP, et al. Impairment of gallbladder emptying in diabetes mellitus. Gastroenterology 1988;95:170-6.
90. Barreto SG, Saccone GT. Alcohol-induced acute pancreatitis: the 'critical mass' concept. Med Hypotheses 2010;75:73-6.
91. Gao W, Bihorel S, Dubois DC, Almon RR, Jusko WJ. Mechanism-based disease progression modelling of type 2 diabetes in goto-kakizaki rats. J Pharmacokinet Pharmacodyn; 2011.
92. Petrov MS, Zagainov VE. Influence of enteral versus parenteral nutrition on blood glucose control in acute pancreatitis: a systematic review. Clin Nutr 2007;26:514-23. (Pubitemid 47618315)